Regeneron Pharmaceuticals, Inc. (REGN) EBITDA Margin: 40.57%
Is Regeneron Pharmaceuticals, Inc.’s EBITDA margin high or low?
Regeneron Pharmaceuticals, Inc.'s EBITDA margin of 40.57% is in line with its 5-year average of 44.24%, near the low end of its 5-year range (35.78%–60.16%).
The EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN) is 40.57% as of Wednesday, June 10, 2026. It is above its 12-month average by 4.00% (39.01%).
REGN EBITDA Margin Chart
REGN Average EBITDA Margin Chart
REGN Current vs Average EBITDA Margin Chart
REGN EBITDA Margin Metrics
EBITDA MARGIN
40.57%
EBITDA MARGIN AVG TTM
39.01%
EBITDA MARGIN AVG 3Y
39.25%
EBITDA MARGIN AVG 5Y
44.24%
EBITDA MARGIN AVG 10Y
40.62%
EBITDA MARGIN AVG 15Y
31.06%
EBITDA MARGIN AVG 20Y
7.99%
CURRENT VS TTM AVG
+4.00%
CURRENT VS 3Y AVG
+3.36%
CURRENT VS 5Y AVG
-8.30%
CURRENT VS 10Y AVG
-0.13%
CURRENT VS 15Y AVG
+30.63%
CURRENT VS 20Y AVG
+407.79%
REGN Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | — | 40.57% | 39.01% | 39.25% | 44.24% |
| Cigna Corporation (CI) | $78.25B | 4.22% | 4.42% | 5.04% | 5.39% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 34.13% | 33.43% | 32.56% | 31.99% |
| Humana Inc. (HUM) | $43.78B | 2.24% | 2.50% | 3.66% | 4.53% |
| Elevance Health Inc. (ELV) | $87.43B | 4.85% | 5.39% | 5.84% | 6.22% |
| Agilent Technologies, Inc. (A) | $37.17B | 26.41% | 27.60% | 26.98% | 26.47% |
| Zoetis Inc. (ZTS) | $34.20B | 42.98% | 42.41% | 42.38% | 41.76% |
| Centene Corporation (CNC) | $31.94B | -2.64% | 0.58% | 1.90% | 2.49% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 21.24% | 21.82% | 21.39% | 20.63% |
| DexCom, Inc. (DXCM) | $29.24B | 24.96% | 24.20% | 23.29% | 21.36% |
Margin Comparison
Gross Margin
84.5%
EBITDA Margin
40.6%
Operating Margin
24.3%
Net Margin
29.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Regeneron Pharmaceuticals, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The EBITDA margin for REGN stock is 40.57%.
- Is Regeneron Pharmaceuticals, Inc.'s EBITDA margin high or low?
- Regeneron Pharmaceuticals, Inc.'s EBITDA margin of 40.57% is in line with its 5-year average of 44.24%, near the low end of its 5-year range (35.78%–60.16%).
- What is the TTM average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average EBITDA margin for REGN stock is 39.01%.
- What is the 3Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average EBITDA margin for REGN stock is 39.25%.
- What is the 5Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average EBITDA margin for REGN stock is 44.24%.
- What is the 10Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average EBITDA margin for REGN stock is 40.62%.
- What is the 15Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average EBITDA margin for REGN stock is 31.06%.
- What is the 20Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average EBITDA margin for REGN stock is 7.99%.
Regeneron Pharmaceuticals, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 40.57% |
| 2024-12-31 | 37.45% |
| 2023-12-31 | 35.78% |
| 2022-12-31 | 43.21% |
| 2021-12-31 | 60.16% |
| 2020-12-31 | 48.29% |
| 2019-12-31 | 40.71% |
| 2018-12-31 | 40.68% |
| 2017-12-31 | 38.30% |
| 2016-12-31 | 29.66% |
| 2015-12-31 | 32.03% |
| 2014-12-31 | 30.71% |
| 2013-12-31 | 38.06% |
| 2012-12-31 | 36.03% |
| 2011-12-31 | -38.25% |
| 2010-12-31 | -16.48% |
| 2009-12-31 | -14.60% |
| 2008-12-31 | -25.72% |
| 2007-12-31 | -65.64% |
| 2006-12-31 | -120.60% |
| 2005-12-31 | -102.57% |
| 2004-12-31 | 39.79% |
| 2003-12-31 | -159.16% |
| 2002-12-31 | -516.19% |
| 2001-12-31 | -362.29% |
| 2000-12-31 | -35.18% |
| 1999-12-31 | -59.13% |
| 1998-12-31 | -24.87% |
| 1997-12-31 | -28.10% |
| 1996-12-31 | -46.47% |
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer